Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wild-type inactivated poliovirus vaccine
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The **wild-type inactivated poliovirus vaccine** is a vaccine using killed (inactivated with formalin) wild-type poliovirus strains—specifically Mahoney (type 1), MEF-1 (type 2), and Saukett (type 3)—to induce immunity against poliomyelitis. Developed originally by Jonas Salk in 1955, the vaccine is produced by culturing poliovirus in cell lines, purifying, and inactivating it with formalin. The vaccine stimulates IgG-mediated immune responses in the bloodstream, protecting against polio-associated paralysis but not inducing strong mucosal immunity. This vaccine type is distinct from the Sabin (sIPV) vaccine, which uses attenuated strains, and from the oral polio vaccine (OPV) which is live-attenuated. Wild-type IPV is administered via injection, primarily for the prevention of poliomyelitis, and is included in many combination vaccines with other pediatric antigens such as DTaP, Hib, and hepatitis B[2][3][4][5][1].
- Other names
- IPV wild-typeSalk IPVwild poliovirus inactivated vaccine
Beyond the preview
Go deeper on wild-type inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wild-type inactivated poliovirus vaccine.